Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

183 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-cell RNAseq identifies clonally expanded antigen-specific T-cells following intradermal injection of gold nanoparticles loaded with diabetes autoantigen in humans.
Hanna SJ, Thayer TC, Robinson EJS, Vinh NN, Williams N, Landry LG, Andrews R, Siah QZ, Leete P, Wyatt R, McAteer MA, Nakayama M, Wong FS, Yang JHM, Tree TIM, Ludvigsson J, Dayan CM, Tatovic D. Hanna SJ, et al. Among authors: dayan cm. Front Immunol. 2023 Oct 16;14:1276255. doi: 10.3389/fimmu.2023.1276255. eCollection 2023. Front Immunol. 2023. PMID: 37908349 Free PMC article.
Gene expression signature predicts rate of type 1 diabetes progression.
Suomi T, Starskaia I, Kalim UU, Rasool O, Jaakkola MK, Grönroos T, Välikangas T, Brorsson C, Mazzoni G, Bruggraber S, Overbergh L, Dunger D, Peakman M, Chmura P, Brunak S, Schulte AM, Mathieu C, Knip M, Lahesmaa R, Elo LL; INNODIA Consortium. Suomi T, et al. EBioMedicine. 2023 Jun;92:104625. doi: 10.1016/j.ebiom.2023.104625. Epub 2023 May 22. EBioMedicine. 2023. PMID: 37224769 Free PMC article.
First-in-human, double-blind, randomized phase 1b study of peptide immunotherapy IMCY-0098 in new-onset type 1 diabetes.
Van Rampelbergh J, Achenbach P, Leslie RD, Ali MA, Dayan C, Keymeulen B, Owen KR, Kindermans M, Parmentier F, Carlier V, Ahangarani RR, Gebruers E, Bovy N, Vanderelst L, Van Mechelen M, Vandepapelière P, Boitard C. Van Rampelbergh J, et al. BMC Med. 2023 May 24;21(1):190. doi: 10.1186/s12916-023-02900-z. BMC Med. 2023. PMID: 37226224 Free PMC article. Clinical Trial.
Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design.
Premawardhana LD, Taylor PN, Okosieme OE, Adlan MA, Obuobie EK, Dayan CM. Premawardhana LD, et al. Among authors: dayan cm. Front Endocrinol (Lausanne). 2023 Nov 16;14:1282608. doi: 10.3389/fendo.2023.1282608. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 38034018 Free PMC article. Review.
183 results